

DOCKET NO.: RTS-0353

PATENT

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1(Canceled).

Claim 2 (Currently amended): The compound of claim 3[[1]] which is an antisense oligonucleotide.

Claim 3(Currently amended): A chemically-modified
~~The compound of claim 2 wherein the antisense~~
~~oligonucleotide 8 to 50 nucleobases in length targeted to~~
~~nucleobases 1018 to 1037 of a nucleic acid molecule~~
~~encoding ABC transporter MHC 1 (SEQ ID NO: 3), wherein said~~
~~compound specifically hybridizes with, and inhibits~~
~~expression of, ABC transporter MHC 1 has a sequence~~
~~comprising SEQ ID NO: 10, 11, 12, 14, 15, 16, 17, 18, 19,~~
~~21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35,~~
~~36, 39, 40, 41, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56,~~
~~57, 58, 59, 60, 63, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74,~~
~~75, 77, 78, 79, 80, 81, 82, 83, 84, 86 or 87.~~

Claim 4(Original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

DOCKET NO.: RTS-0353

PATENT

Claim 5(Original): The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

Claim 6(Original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

Claim 7(Original): The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

Claim 8(Original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

Claim 9(Original): The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

Claim 10(Original): The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

Claim 11(Canceled).

Claim 12(Currently amended): A composition comprising the compound of claim 3[[1]] and a pharmaceutically acceptable carrier or diluent.

Claim 13(Original): The composition of claim 12

DOCKET NO.: RTS-0353

PATENT

further comprising a colloidal dispersion system.

Claim 14(Original): The composition of claim 12 wherein the compound is an antisense oligonucleotide.

Claim 15(Withdrawn-currently amended): A method of inhibiting the expression of ABC transporter MHC 1 in cells or tissues comprising contacting said cells or tissues with the compound of claim 3[[1]] so that expression of ABC transporter MHC 1 is inhibited.

Claim 16(Withdrawn-currently amended): A method of treating an animal having a disease or condition associated with ABC transporter MHC 1 comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 3[[1]] so that expression of ABC transporter MHC 1 is inhibited.

Claim 17(Withdrawn): The method of claim 16 wherein the disease or condition is a hyperproliferative disorder.

Claim 18(Withdrawn): The method of claim 16 wherein the disease or condition is an autoimmune disorder.

Claims 19-20(Canceled).

Claim 21 (New): A chemically-modified compound 8 to 50 nucleobases which specifically hybridizes with a portion of an active site on a nucleic acid molecule of SEQ

DOCKET NO.: RTS-0353

PATENT

ID NO: 3 encoding ABC transporter MHC 1, wherein said active site is a sequence spanning nucleobases 1018 to 1037 of SEQ ID NO: 3 and wherein said compound inhibits expression of said molecule encoding ABC transporter MHC 1.

Claim 22 (New): The compound of 21 which is an antisense oligonucleotide.